LY4167586 + Placebo + LY4167586
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight
Conditions
Overweight, Obesity
Trial Timeline
Nov 18, 2025 → Dec 1, 2026
NCT ID
NCT07225556About LY4167586 + Placebo + LY4167586
LY4167586 + Placebo + LY4167586 is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225556. Target conditions include Overweight, Obesity.
What happened to similar drugs?
1 of 20 similar drugs in Overweight were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07225556 | Phase 1 | Recruiting |
Competing Products
20 competing products in Overweight
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 32 |
| LY3457263 + Tirzepatide + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3305677 + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3537031 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection) | Eli Lilly | Phase 2 | 42 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 47 |
| LY4064912 + LY4064912 + Placebo + Placebo | Eli Lilly | Phase 1 | 36 |
| LY3437943 + Ethinyl Estradiol + Drospirenone | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Acetaminophen | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 39 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 47 |
| LY3437943 + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3502970 + Placebo | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 44 |
| Eloralintide and Tirzepatide + Eloralintide | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 40 |
| LY3541105 + Placebo | Eli Lilly | Phase 1 | 29 |
| Retatrutide + Placebo | Eli Lilly | Phase 2 | 35 |
| AZD9550 + AZD6234 + Placebo comparator | AstraZeneca | Phase 2 | 39 |
| pramlintide acetate + sibutramine + phentermine + placebo | AstraZeneca | Phase 2 | 35 |